<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04080167</url>
  </required_header>
  <id_info>
    <org_study_id>mESH</org_study_id>
    <secondary_id>5U01HL133996</secondary_id>
    <nct_id>NCT04080167</nct_id>
  </id_info>
  <brief_title>Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization</brief_title>
  <official_title>Integration of mHEALTH Into the Care of Patients With Sickle Cell Disease to Increase Hydroxyurea Utilization- mESH Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>St. Jude Children's Research Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>RTI International</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Memphis</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>St. Jude Children's Research Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This project proposes to develop, test and evaluate targeted interventions to improve
      clinical provider prescribing of and patient adherence to hydroxyurea (HU). Using a
      stepped-wedge design, The investigators will test two innovative interventions utilizing
      mobile health to address both patients' and providers' needs: 1) an mHealth application for
      patients (InCharge Health app) that includes multi-component features to address the memory,
      motivation, and knowledge barriers to hydroxyurea use, and 2) an mHealth toolbox application
      for providers (HU Toolbox app) that addresses clinical knowledge barriers in prescribing and
      monitoring hydroxyurea use. These two interventions will be tested through the following
      aims:

      Aim 1. Improve Patient Adherence to Hydroxyurea: Addressing Memory, Motivation, and Knowledge
      Barriers to Hydroxyurea Use. Primary hypothesis: The investigators hypothesize that among
      adolescents and adults with SCD, the adherence to hydroxyurea, as measured by proportion of
      daily coverage (PDC), will increase by at least 20% at 24 weeks after receiving the InCharge
      Health app, compared to their hydroxyurea adherence at baseline.

      Sub-aim 1.a. To examine and assess both patient engagement and behaviors related to use of
      the InCharge Health app, the investigators will evaluate consistent use of the app among
      enrolled patients, patient satisfaction, and continued use of the app beyond the study
      period.

      Sub-Aim 1.b. To examine the clinical influence of the use of the InCharge Health app on PDC,
      patients' clinical outcomes, perceived health literacy, health related quality of life, and
      perceived self-efficacy between baseline and 24 weeks.

      Aim 2. Improve Provider Hydroxyurea Awareness, Prescribing and Monitoring Behaviors.

      Sub-Aim 2.a. To examine and assess provider engagement and behaviors related to use of the HU
      Toolbox, the investigators will evaluate consistent use of the app among enrolled providers,
      providers' satisfaction, and continued use of the app beyond the study period.

      Sub-Aim 2.b. To assess the combined effects of the patient and provider mHealth interventions
      on hydroxyurea and health care utilization, the investigators will examine if the changes in
      hydroxyurea adherence are enhanced by the use of both provider and patient interventions
      compared to those not exposed to one or both interventions.

      Aim 3. Identify and Evaluate the Barriers and Facilitators to the use of mHealth
      Interventions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The National Heart, Lung, and Blood Institute (NHLBI) created the Sickle Cell Disease
      Implementation Consortium (SCDIC) to apply implementation science methods to identify and
      address barriers to guideline-based care in sickle cell disease (SCD) and promote
      evidence-based treatment for SCD patients between ages 15 to 45 years. The SCDIC conducted a
      systematic literature review and a comprehensive needs assessment among the eight
      participating centers. A major conclusion was that care redesign to support better
      hydroxyurea utilization would likely improve clinical outcomes for patients with SCD.
      Hydroxyurea therapy has been shown to improve patient outcomes and reduce disease
      complications and is endorsed by the NHLBI. SCDIC now proposes to develop, test and evaluate
      targeted interventions to improve clinical provider prescribing of and patient adherence to
      hydroxyurea.

      The overall purpose of this proposed project is to address barriers identified by the needs
      assessment to improve adherence with hydroxyurea therapy. Multiple approaches for improving
      adherence with pharmaceutical regimens have been studied and demonstrate a need to address
      barriers that both providers and patients face. This project aims, via a stepped-wedge
      design, to test two innovative interventions utilizing mobile health (mHealth), to address
      both patients' and providers' needs: 1) an mHealth application for patients (InCharge Health
      app) that includes multi-component features to address the memory, motivation, and knowledge
      barriers to hydroxyurea use, and 2) an mHealth toolbox application for providers (HU Toolbox
      app) that addresses the clinical knowledge barriers in prescribing and monitoring hydroxyurea
      use. These two interventions will be tested through the following aims:

      Aim 1. Improve Patient Adherence to Hydroxyurea: Addressing Memory, Motivation, and Knowledge
      Barriers to Hydroxyurea Use. Primary hypothesis: The investigators hypothesize that among
      adolescents and adults with SCD, the adherence to hydroxyurea, as measured by proportion of
      daily coverage (PDC), will increase by at least 20% at 24 weeks after receiving the InCharge
      Health app, compared to their hydroxyurea adherence at baseline.

      Sub-aim 1.a. To examine and assess both patient engagement and behaviors related to use of
      the InCharge Health app, the investigators will evaluate consistent use of the app among
      enrolled patients, patient satisfaction, and continued use of the app beyond the study
      period.

      Sub-Aim 1.b. To examine the clinical influence of the use of the InCharge Health app on PDC,
      patients' clinical outcomes, perceived health literacy, health related quality of life, and
      perceived self-efficacy between baseline and 24 weeks.

      Aim 2. Improve Provider Hydroxyurea Awareness, Prescribing and Monitoring Behaviors. The
      investigators will examine among providers using the HU Toolbox App if there is an increase
      in reported awareness of hydroxyurea benefits and risks, accurate prescribing of hydroxyurea,
      and perceived self-efficacy to correctly administer hydroxyurea therapy between baseline and
      after 9 months of using the HU Toolbox app.

      Sub-Aim 2.a. To examine and assess provider engagement and behaviors related to use of the HU
      Toolbox, the investigators will evaluate consistent use of the app among enrolled providers,
      providers' satisfaction, and continued use of the app beyond the study period.

      Sub-Aim 2.b. To assess the combined effects of the patient and provider mHealth interventions
      on hydroxyurea and health care utilization, the investigators will examine if the changes in
      hydroxyurea adherence are enhanced by the use of both provider and patient interventions
      compared to those not exposed to one or both interventions.

      Aim 3. Identify and Evaluate the Barriers and Facilitators to the use of mHealth
      Interventions. The investigators will evaluate the strategies used by participating sites in
      supporting the implementation of mHealth interventions via a mixed-method evaluation of the
      facilitators and barriers in adopting and implementing the mHealth interventions from
      multiple stakeholder perspectives: patient, provider, and organization.

      Both mHealth interventions will be tested concurrently and because the investigators are
      using a stepped-wedge design, each site will enter the study at different times. Provider
      participants will receive the HU Toolbox intervention for 9 months with a lagged but
      overlapping introduction of the InCharge Health intervention patient participants for 24
      weeks. The implementation evaluation will be guided by RE-AIM to assess the Reach,
      Effectiveness, Adoption, Implementation and Maintenance of the interventions. All sites will
      also complete follow-on needs assessment and medical record abstractions that will provide
      data to evaluate other patient and provider outcomes, barriers and enablers to hydroxyurea
      prescribing, use, and monitoring.

      mHealth technology can be leveraged to support more effective use of hydroxyurea and
      eventually improved SCD clinical outcomes. If the mHealth applications tested in this study
      show preliminary efficacy, both apps could be scaled up within SCDIC centers and expanded to
      other institutions outside the SCDIC.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 11, 2019</start_date>
  <completion_date type="Anticipated">June 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>nonrandomized, closed cohort, stepped-wedge cluster trial</intervention_model_description>
    <primary_purpose>Health Services Research</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measure of the association between InCharge Health app to patient hydroxyurea adherence</measure>
    <time_frame>baseline (prior to the intervention), week 12, week 24</time_frame>
    <description>The primary outcome is the change in proportion of days covered (PDC) of hydroxyurea from baseline (prior the intervention) to week 24. PDC is calculated as the number of days covered (i.e., days of prescription refill dates and supply of each prescription) divided by the number of days in a treatment time point then multiple by 100 to obtain the PDC as a percentage.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Implementation of InCharge Health app.</measure>
    <time_frame>baseline, 24 weeks, 36 weeks</time_frame>
    <description>Proportion and representativeness of patients participating/enrolled in the study (numerator) among all patients who receive hydroxyurea treatment and were eligible (denominator) at each site.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean corpuscular volume (MCV)</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>Mean MCV</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in fetal hemoglobin</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>Mean fetal hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean hemoglobin concentration</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>Mean hemoglobin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in absolute reticulocyte count</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>Mean absolute reticulocyte count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in absolute neutrophil count (ANC)</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>Mean ANC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in bilirubin (indirect)</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>Mean indirect bilirubin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean plasma lactate dehydrogenase (LDH)</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>Mean LDH</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in rate of emergency room visits per patient per year</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>Frequency of emergency room visits per patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in rate of hospitalization per patient per year</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>Frequency of hospitalizations per patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported pain quality</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>Patient reported outcomes information system (PROMIS) pain quality scale (never, rarely, sometimes, often, always)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported pain impact: ASCQ-Me Pain Impact scale</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>The Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) Pain Episode Frequency and Severity Scale (never, rarely, sometimes, often, always)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in patient reported pain frequency and severity</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>The Adult Sickle Cell Quality of Life Measurement Information System (ASCQ-Me) Pain Episode Frequency and Severity scale (never, rarely, sometimes, often, always)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in healthy literacy</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>Single item literacy screener (SILS). (Never, rarely, sometimes, often, always)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in perceived self-efficacy</measure>
    <time_frame>baseline, 24 weeks</time_frame>
    <description>Patient reported outcomes information system (PROMIS) medication self-efficacy short form (I am not at all confident, I am a little confident, I am somewhat confident, I am quite confident, and I am very confident)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in provider knowledge of hydroxyurea (HU) prescription guidelines</measure>
    <time_frame>baseline, 9 months</time_frame>
    <description>Hydroxyurea knowledge scale (comfort level and effectiveness in prescribing hydroxyurea from 0 to 5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change is provider self-efficacy of hydroxyurea (HU) prescription guidelines</measure>
    <time_frame>baseline, 9 months</time_frame>
    <description>Hydroxyurea self-efficacy scale (comfort level and effectiveness in prescribing hydroxyurea from 0 to 5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Implementation of the HU Toolbox</measure>
    <time_frame>baseline, 36 weeks, 48 weeks</time_frame>
    <description>Mean change in provider satisfaction and proportion of providers that use the toolbox app at least once a week based on monthly clicks.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Combined effects of the patient and provider mHealth interventions</measure>
    <time_frame>baseline, 36 weeks</time_frame>
    <description>Patients' proportion of daily coverage and hospitalizations and emergency department visits per patient.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">368</enrollment>
  <condition>Sickle Cell Disease</condition>
  <arm_group>
    <arm_group_label>Arm 1 (InCharge Health app)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Patient receives the InCharge Health app for 6 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2 (HU Toolbox app)</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Provider receives the HU Toolbox app for 9 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>InCharge Health mobile application</intervention_name>
    <description>The InCharge Health app features include: Daily reminders; Ability to customize content of message and time of day when the message comes; Symptom tracker to monitor daily pain and mood; 7-day streak that tracks daily adherence; Graphing adherence against pain symptoms; Communication feature allowing the patient to connect to the clinic and a &quot;health partner&quot;; Link to discussion forum where communication to other patients can occur; Education bank that provides information about SCD and hydroxyurea. Participants can delay daily push notifications. If hospitalized, participants may stop notifications. A special feature of the app is to set up a &quot;health partner&quot;, who may be a person the participant may choose from his/her contact list and who will receive notifications if it had been &lt;4 hours since not documenting the use of hydroxyurea. The &quot;app healthy partner&quot; will be encouraged to message the participant to remind him/her to take the medication.</description>
    <arm_group_label>Arm 1 (InCharge Health app)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>HU Toolbox mobile application</intervention_name>
    <description>The HU Toolbox app includes algorithms for hydroxyurea use and is ready for immediate use on Apple and Android operating systems. In addition, it has the NHLBI guidelines adapted for pediatrics (guidelines/recommendations separated by age) and for adults (guidelines/ recommendations separated by organ system, laboratory, or physical exam finding). The HU Toolbox app includes the ability to search guidelines for key words and add notes. Algorithms are also included as PDF documents that can be printed out or emailed. Finally, a contact list of local SCD specialists and important contacts is included, so providers can easily contact SCD experts and expect an answer in 24 hours or less. The HU Toolbox app is easily updated with all data and resources stored on a cloud-based server that can provide instant up-to-date information to those using the app.</description>
    <arm_group_label>Arm 2 (HU Toolbox app)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 15 years up to and including 45 years

          -  Treated at or affiliated with one of the SCDIC sites

          -  English speaking

          -  Confirmed Sickle Cell Disease (SCD) diagnosis. An SCD diagnosis is defined as Hb
             fractionation test (e.g., high- performance liquid chromatography or another
             technique) that is diagnostic of one the following: Hb SS, Hb SC, Hb SÎ²-thalassemia,
             Hb SO, Hb SD, Hb SG, Hb SE, or Hb SF.

          -  Willing and cognitively able to give informed consent

          -  Access to a cellular/mobile smart phone (either Android or IPhone are acceptable)

          -  Hydroxyurea therapy: Already receiving hydroxyurea therapy: defined as at least one
             prior prescription to hydroxyurea in the past 3 months. Initiating hydroxyurea
             therapy: defined as at least one prescription written at the time of study enrollment
             (the first prescription must be written on the same day as study enrollment). Patients
             who initiate hydroxyurea on the same day of study enrollment will not contribute to
             the total of 52 patients target accrual for the site. A max of 30 patients who are
             initiating hydroxyurea can be enrolled per site.

        Exclusion Criteria:

          -  Current pregnancy

          -  On a chronic transfusion program in which they receive more than 8 erythrocyte
             transfusions in a 12-month period.

          -  A red blood cell transfusion in the past 60 days

          -  Currently using another phone application or an online-based tool (e-health tool) to
             increase hydroxyurea adherence
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jane Hankins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>St. Jude Children's Research Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jane Hankins, MD</last_name>
    <phone>866-278-5833</phone>
    <email>referralinfo@stjude.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of California San Francisco</name>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marsha Treadwell, PhD</last_name>
      <phone>510-428-3168</phone>
      <email>marsha.treadwell@ucsf.edu</email>
    </contact>
    <investigator>
      <last_name>Marsha Treadwell, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Georgia Regents University</name>
      <address>
        <city>Augusta</city>
        <state>Georgia</state>
        <zip>30912</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abdulah Kutlar, MD</last_name>
      <phone>706-721-2171</phone>
      <email>akutlar@augusta.edu</email>
    </contact>
    <investigator>
      <last_name>Abdulah Kutlar, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Gordeuk, MD</last_name>
      <phone>312-996-5680</phone>
      <email>vgordeuk@uic.edu</email>
    </contact>
    <investigator>
      <last_name>Victor Gordeuk, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Washington University</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Allison King, MD, PhD, MPH</last_name>
      <phone>314-454-6018</phone>
      <email>king_a@wustl.edu</email>
    </contact>
    <investigator>
      <last_name>Allison King, MD, PhD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lynn Richardson, MD</last_name>
      <phone>212-824-8066</phone>
      <email>Lynne.Richardson@mssm.edu</email>
    </contact>
    <investigator>
      <last_name>Lynn Richardson, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Duke University</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nirmish Shah, MD</last_name>
      <phone>919-668-5178</phone>
      <email>nirmish.shah@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Nirmish Shah, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cathy Melvin, PhD</last_name>
      <phone>843-876-2426</phone>
      <email>melvinc@musc.edu</email>
    </contact>
    <investigator>
      <last_name>Cathy Melvin, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Jude Children's Research Hospital</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chinonyelum Nwosu, MPH</last_name>
      <phone>901-595-7566</phone>
      <email>chinonyelum.nwosu@stjude.org</email>
    </contact>
    <contact_backup>
      <last_name>Hamda Khan, MA</last_name>
      <phone>901-595-0294</phone>
      <email>hamda.khan@stjude.org</email>
    </contact_backup>
    <investigator>
      <last_name>Jane Hankins, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.stjude.org</url>
    <description>St. Jude Children's Research Hospital</description>
  </link>
  <link>
    <url>http://www.stjude.org/protocols</url>
    <description>ClinicalTrials Open at St. Jude</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>August 15, 2019</study_first_submitted>
  <study_first_submitted_qc>September 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">September 6, 2019</study_first_posted>
  <last_update_submitted>May 12, 2020</last_update_submitted>
  <last_update_submitted_qc>May 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>implementation science</keyword>
  <keyword>sickle cell anemia</keyword>
  <keyword>digital medicine</keyword>
  <keyword>adherence</keyword>
  <keyword>hydroxycarbamide</keyword>
  <keyword>health innovation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anemia, Sickle Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant de-identified datasets containing the variables analyzed in the published article will be made available (related to the study primary or secondary objectives contained in the publication). Supporting documents such as the protocol, statistical analyses plan, and informed consent are available through the CTG website for the specific study. Data used to generate the published article will be made available at the time of article publication. Investigators who seek access to individual level de-identified data will contact the computing team in the Department of Biostatistics (ClinTrialDataRequest@stjude.org) who will respond to the data request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Data will be made available at the time of article publication.</ipd_time_frame>
    <ipd_access_criteria>Data will be provided to researchers following a formal request with the following information: full name of requestor, affiliation, data set requested, and timing of when data is needed. As an informational point, the lead statistician and study principal investigator will be informed that primary results datasets have been requested.</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

